201 4 Hann SK, Chun WH: Autocytotoxic hypothesis for the destruction of melanocytes as the cause of vitiligo; in Hann SK, Nordlund JJ (eds): Vitiligo. Oxford, Blackwell Science, 2000, pp 137–141. 5 Bystryn JC: Serum antibodies in vitiligo patients. Clin Dermatol 1989;7: 136–145. 6 Ortonne JP, Bose SK: Vitiligo: Where do we stand? Pigment Cell Res 1993; 8:61–72. 7 Schallreuter KU, Levenig C, Berger J: Vitiligo and cutaneous melanoma: A case study. Dermatologica 1991;183:239–245. 8 Lerner AB, Cage GW: Melanoma in horses. Yale J Biol Med 1973;46:646– 649. 9 Millikan LE, Hook RR, Manning PJ: Gross and ultrastructural studies in a new melanoma model: The Sinclair swine. Yale J Biol Med 1973;46:631– 645. 10 Milton GW, McCarthy WH, Carlon A: Malignant melanoma and vitiligo. Australas J Dermatol 1971;12:131–142. 11 Klaus SN, Lerner AB: Vitiligo. J Am Acad Dermatol 1984;11:997–1000. 12 Itin PH, Lautenschlager S: Acquired leukoderma in congenital pigmented nevus associated with vitiligo-like depigmentation. Pediatr Dermatol 2002;9:73–75. 13 Kestel JL: Giant pigmented nevus with vitiligo. Tex Med 1966;62:52–54. 14 Barriere H, Litoux P, Le Lay M, Bureau B, Stalder JF, Dreno B: Cutaneous achromia and malignant melanoma. Ann Dermatol Vénéréol 1984;111: 991–996. 15 Lerner AB, Kirkwood JM: Vitiligo and melanoma: Can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family? J Am Acad Dermatol 1984;11:696–701. 16 Lerner AB, Nordlund JJ: Should vitiligo be induced in patients after resection of primary melanoma? Arch Dermatol 1977;113:421. 17 Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V: High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203–1208. 18 van den Wijngaard R, Wankowicz-Kalinska A, Pals S, Weening J, Das P: Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001;8:1061– 1067. 19 Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC: A symbiotic concept of autoimmunity and tumour immunity: Lessons from vitiligo. Trends Immunol 2001:22:130–136. 20 Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, Fabbri P: New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87–92.
[1]
L. Cerroni,et al.
Hypopigmented Mycosis Fungoides: Frequent Expression of a CD8+ T-Cell Phenotype
,
2002,
The American journal of surgical pathology.
[2]
M. Grunwald,et al.
Localized Hypopigmented Mycosis Fungoides in a 12‐Year‐Old Caucasian Boy
,
1999,
The Journal of dermatology.
[3]
L. Naldi,et al.
A Case of Hypopigmented Mycosis Fungoides in a Young Caucasian Boy
,
1997,
Pediatric dermatology.
[4]
M. Lebwohl,et al.
Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases.
,
1995,
Journal of the American Academy of Dermatology.
[5]
N. Smith,et al.
Hypopigmented mycosis fungoides: report of five cases with ultrastructural observations
,
1982,
The British journal of dermatology.